The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Sign Up to like & getrecommendations! Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.69
Abstract: The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways read more here.
Keywords: alkylating hdac; edo s101; inhibitor edo; class alkylating ... See more keywords